Allergy Therapeutics
Sustainability Report and Carbon Intensity Rankings
Is Allergy Therapeutics doing their part?
Their DitchCarbon score is 58
Allergy Therapeutics has a DitchCarbon Score of 58 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, which is a measure of the greenhouse gases emitted relative to the value they generate. A higher score would suggest a lower carbon intensity and a stronger commitment to reducing emissions.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Allergy Therapeutics is part of the industrial manufacturing sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Allergy Therapeutics is situated in the UK, which has a very low carbon intensity rating, indicating a cleaner energy grid. This favorable location supports the company’s sustainability efforts by reducing its carbon footprint through the use of greener energy sources.
Unlock 30+ emissions data points on Allergy Therapeutics
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Allergy Therapeutics
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
16.71%
...this company is doing 16.71% better in emissions than the industry average.
Allergy Therapeutics, founded in 1998, is situated in Worthing, Europe, and operates within the industrial manufacturing sector. The company specializes in the healthcare field, particularly in the diagnosis and treatment of allergies. It offers a range of pharmaceutical products and services aimed at improving the lives of patients with allergic conditions.
emission intelligence's platform recommendations for Allergy Therapeutics
Allergy Therapeutics should consider investing in energy-efficient appliances and equipment to potentially reduce their scope 2 emissions from purchased electricity by 20%.
Good news, Allergy Therapeutics has embraced SBTi commitments
Allergy Therapeutics has committed to significantly reducing their greenhouse gas emissions from company operations, which include direct emissions and indirect emissions from purchased energy. Their targets align with the international goal to limit global warming to 1.5°C, reflecting a strong commitment to environmental sustainability.
Participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.